Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single Arm, Multicenter, Phase 2 Study of BGB-A317 as Monotherapy in Relapsed or Refractory Classical Hodgkin Lymphoma

NCT03209973 is registered in ClinicalTrials.gov with BeiGene as lead sponsor.

NCT NCT03209973
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03209973 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single Arm, Multicenter, Phase 2 Study of BGB-A317 as Monotherapy in Relapsed or Refractory Classical Hodgkin Lymphoma
Lead sponsor
BeiGene
Phase
Phase 2
Overall status
Completed
Start date
April 21, 2017
Completion date
November 2, 2020
Enrollment
70 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

classical hodgkin lymphoma